https://t.co/5EehCyFkG9
Compounds that recruit FKBP12 to novel targets with high cooperativity are the prototypical molecular glue and, represented by sirolimus and tacrolimus, have had major clinical impact. 1/3
@wgibson Really cool story, Will. Hard to predict the functional outcome of recruitment! Excited to see what the field will learn about requirements for activation vs RIPTAC as more TFs are aTAGed. Maybe ChIP-Seq first can find candidates that aren’t pre-occupied with p300
@bloodgenes@OmicsOmicsBlog@NewYorker I like selective disruption of the repressive complex but PPI inhibition is hard. Another option: Crabtree/Gray TCIP: cmpd-induced proximity of TF activator (eg P300) to the MECOM-CTBP complex to mimic dCAS9-VP64 cisRE expt. Hail Mary : EZH2i or similar for general derepession.
@walmer_bolfet@lydiakauppi@esjesjesj Development of daraxonrasib, a tri-complex cyclophilin K-RAS inhibitor, by Revolution Medicines: a company combined academic discoveries from the mechanism of the FK506 molecular glue (Schreiber), to KRAS biology (McCormick) and targeting (Shokat). This is a common pharma story.
@Bbq11tx@AriFleischer@lizleigh923 The goal of zebrafish studies is not about zebrafish, but principles of biology common between organisms. Unlike other animals, Zebrafish are easy to study! They help us learn human biology and develop therapies. Brain disorders are an unsolved problems and zebrafish can help!
@MedGold_ Canada is our largest trading partner, we import $481 billion of goods and services and export $427 billion. Compare to China where we import $563 billion, export only $196 billion. https://t.co/RCtp7HSkpR https://t.co/ri8r5j42Bo
I'm happy and humbled to take on a new role with @buildmodels . I'll be continuing @dsgoodsell's work on the Molecule of the Month, starting with my first article on Assembly Line Polyketide Synthases! Check it out (animation included!)
https://t.co/ZmrB84V7EF
@philipposopher@hubermanlab@MattMurrie A drug will activate/inhibit multiple receptors/proteins. These receptors/proteins can be related or completely different. This is promiscuity and is the rule rather than the exception of small molecule drugs. Also a receptor/protein’s function can differ in different tissue.
@elonmusk “The last unilateral dissolution of Parliament by a monarch occurred in 1835.” This was under William IV - prior to even Queen Victoria. https://t.co/8GrE7bIwVk
@sims67127@benonwine https://t.co/8GrE7bIwVk “The last unilateral dissolution of Parliament by a monarch occurred in 1835.” This was under William IV - prior to even Queen Victoria.
@drmarkhyman The logical conclusion of your spiel is avoidance of fried food and barbecued meats to lower risk of colon cancer… not controversial at all. American Heart Association recommended seed oils to minimize saturated fat, that doesn’t make deep fried food healthy.
We showed that novel, pre-selected targets can be recruited to FKBP12 with cooperativity, i.e., with molecular glues. Moving from discovery to characterization with biophysical (including structural) and cellular studies we are contributing to the blueprint of glue discovery. 3/3
https://t.co/5EehCyFkG9
Compounds that recruit FKBP12 to novel targets with high cooperativity are the prototypical molecular glue and, represented by sirolimus and tacrolimus, have had major clinical impact. 1/3
I was gratefully able to be a postdoc in an industry-academic hybrid team in Discovery Sciences (Gregory Michaud) and Global Discovery Chemistry (Frederic Zecri) of Novartis with the Chemical Biology and Therapeutics Science of the Broad Institute (Prof. @SchreiberStuart ). 2/3